RxDoctor Payments DataLook up a doctor →

Keith Kirby, MD

Pain Medicine · Savannah, GANPI 1265518328

Payments from drug & device makers

$7,998in general payments, 2019–2025

Across 454 payments — averaging $17.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$2K
  • Collegium Pharmaceutical, Inc.$949
  • Boston Scientific$791
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$630
  • AbbVie$482
  • Biodelivery Sciences International, Inc.$399
  • plus $3K from 42 others

What the payments were for

  • Food & beverage$7,977100%
  • Education$210%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,998 in reported general payments places this provider in the 80th percentile of 203 pain medicine providers in Georgia.

See all pain medicine providers in Georgia

Medicare billing

Part B allowed, 2024
$51,881
Medicare patients
167
Services billed
583

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Xtampza ErOxycodone Myristate89$55,780
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen2,091$46,889
OxycontinOxycodone Hcl76$45,510
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen914$26,207
Morphine Sulfate ErMorphine Sulfate807$23,032
Nucynta ErTapentadol Hcl13$19,440
Oxycodone Hcl859$17,173
Fentanyl107$13,050
NucyntaTapentadol Hcl12$6,750
Morphine Sulfate149$4,516
Hydromorphone Hcl88$1,664
Methadone Hcl66$907
Gabapentin63$754
Pregabalin37$640
Buprenorphine Hcl11$431

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Collegium Pharmaceutical, Inc.Xtampza Er, Nucynta Er, Nucynta$949$81,970114 claims
Hikma Pharmaceuticals USAMorphine Sulfate, Buprenorphine Hcl$40$4,947160 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 203 pain medicine providers in Georgia.

Other pain medicine in Savannah

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →